Angel investing in medical technology can be tough. The science is complex, the timelines are long, and the risks are hard to judge without the right expertise in the room. At the New York Angels, that has changed. In this New York Angels edition of The Angel Nest, we meet NYA members and medical experts Vijay Aggarwal, PhD and John Younger, and learn how they evaluate life science opportunities. Joining them is Greg Fischer, founder and CEO of AIM Medical Robotics, one of the standout companies the New York Angels chose to fund. AIM is bringing a compact surgical robot to neurosurgery that works inside an MRI scanner in real time. The core problem it solves has haunted neurosurgeons for decades: the brain moves during surgery. Targets the size of a grain of rice can shift millimeters to centimeters mid-procedure, making preoperative maps unreliable exactly when precision matters most. AIM's robot continuously updates its guidance using live MRI imaging for conditions including Parkinson's disease, epilepsy, and brain cancer. Greg, Vijay, and John discuss what it takes to evaluate a medtech company before there is revenue, why AIM's FDA path is unusually clean, how existing reimbursement codes remove one of the biggest commercialization headaches in medical devices, and what the next wave of medtech investment looks like. Learn more about AIM Medical Robotics and find out who the New York Angels are partnering with at newyorkangels.com. Reach us with comments and listen to past episodes at theangelnest.com.